Celiac disease 2015 update: New therapies

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue 7, 2015, Pages 913-927

  Veeraraghavan, Gopal ^a   Leffler, Daniel A ^a   Kaswala, Dharmesh H ^a   Mukherjee, Rupa ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

ALV003; AT 1001; CCR9 antagonist; celiac disease; drug therapy; gluten free diet; larazotide acetate; Necator americanus; Nexvax2; tTG inhibitors

Indexed keywords

BL 7010; CD20 ANTIBODY; CD3 ANTIBODY; CYSTAMINE; GASTROINTESTINAL AGENT; GLUTEN VACCINE; INFLIXIMAB; KCC 009; LARAZOTIDE; LATIGLUTENASE; PLACEBO; PROBIOTIC AGENT; PROLYL ENDOPEPTIDASE; RECOMBINANT INTERLEUKIN 10; STAN 1; TOFACITINIB; UNCLASSIFIED DRUG; VACCINE; VERCIRNON; AT-1001; GLUTEN; GUANINE NUCLEOTIDE BINDING PROTEIN; OLIGOPEPTIDE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEINASE;

ASPERGILLUS NIGER; BIFIDOBACTERIUM INFANTIS; CELIAC DISEASE; CROHN DISEASE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GENOTYPE ENVIRONMENT INTERACTION; GLUTEN FREE DIET; HOOKWORM INFECTION; HUMAN; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; NAUSEA; NECATOR AMERICANUS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TIGHT JUNCTION; TREATMENT DURATION; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; DRUG DEVELOPMENT; DRUG EFFECTS; IMMUNOLOGY; INTESTINE CELL; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY;

CELIAC DISEASE; COMBINED MODALITY THERAPY; DIET, GLUTEN-FREE; DRUG DISCOVERY; ENDOPEPTIDASES; ENTEROCYTES; GLUTENS; GTP-BINDING PROTEINS; HOOKWORM INFECTIONS; HUMANS; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; OLIGOPEPTIDES; PROBIOTICS; TIGHT JUNCTIONS; TRANSGLUTAMINASES; VACCINES;

EID: 84931835176     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1033399     Document Type: Review

References (95)

1. Ludvigsson JF, Montgomery SM, Ekbom A, et al. Small-intestinal histopathology and mortality risk in celiac disease. JAMA 2009;302:1171-8
2. Di Sabatino A, Corazza GR. Coeliac disease. Lancet 2009;373:1480-93
3. Mäki M, Mustalahti K, Kokkonen J, et al. Prevalence of Celiac disease among children in Finland. N Engl J Med 2003;348: 2517-24
4. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States. Arch Intern Med 2003;163:286
5. Fuchs V, Kurppa K, Huhtala H, et al. Factors associated with long diagnostic delay in celiac disease. Scand J Gastroenterol 2014;49:1304-10
6. Green PH, Cellier C. Celiac disease. N Engl J Med 2007;357:1731-43
7. Castillo NE, Theethira TG, Leffler DA. The present and the future in the diagnosis and management of celiac disease. Gastroenterol Rep (Oxf) 2015;3(1):3-11
8. Ivarsson A, Persson LA, Juto P, et al. High prevalence of undiagnosed coeliac disease in adults: A Swedish population-based study. J Intern Med 1999;245:63-8
9. Mukherjee R, Kelly CP, Schuppan D. Nondietary therapies for celiac disease. Gastrointest Endosc Clin N Am 2012;22: 811-31
10. Crespo Perez L, Castillejo De Villasante G, Cano Ruiz A, et al. Non-dietary therapeutic clinical trials in coeliac disease. Eur J Intern Med 2012;23:9-14
11. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002;297:2275-80
12. Sollid LM. Molecular basis of celiac disease. Annu Rev Immunol 2000;18:53-81
13. Jabri B, Sollid LM. Tissue-mediated control of immunopathology in coeliac disease. Nat Rev Immunol 2009;9:858-70
14. Lebwohl B, Murray JA, Rubio-Tapia A, et al. Predictors of persistent villous atrophy in coeliac disease: A population-based study. Aliment Pharmacol Ther 2014;39:488-95
15. Hall NJ, Rubin GP, Charnock A. Intentional and inadvertent non-adherence in adult coeliac disease. A cross-sectional survey. Appetite 2013;68:56-62
16. Leffler DA, Dennis M, Hyett B, et al. Etiologies and predictors of diagnosis in nonresponsive celiac disease. Clin Gastroenterol Hepatol 2007;5:445-50
17. Shah S, Akbari M, Vanga R, et al. Patient perception of treatment burden is high in celiac disease compared with other common conditions. Am J Gastroenterol 2014;109: 1304-11
18. Tennyson CA, Simpson S, Lebwohl B, et al. Interest in medical therapy for celiac disease. Therap Adv Gastroenterol 2013;6: 358-64
19. U.S. Food and Drug Administration. The FDA's Drug Review Process: ensuring Drugs Are Safe and Effective. Available from: http://www.fda.gov/drugs/ resourcesforyou/consumers/ucm143534.htm [Accessed 7 March 2015
20. Lähdeaho M-L, Lindfors K, Airaksinen L, et al. Recent advances in the development of new treatments for celiac disease. Expert Opin Biol Ther 2012;12:1589-600
21. Kelly CP, Green PHR, Murray JA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge: A randomised placebo-controlled study. Aliment Pharmacol Ther 2013;37:252-62
22. Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol 2012;107:1554-62
23. Lohiniemi S, Maki M, Kaukinen K, et al. Gastrointestinal symptoms rating scale in coeliac disease patients on wheat starch-based gluten-free diets. Scand J Gastroenterol 2000;35:947-9
24. Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: A randomized controlled trial. Gastroenterology 2015. [Epub ahead of print]
25. Mustalahti K, Lohiniemi S, Collin P, et al. Gluten-free diet and quality of life in patients with screen-detected celiac disease. Eff Clin Pract 2002;5:105-13
26. Menard S, Lebreton C, Schumann M, et al. Paracellular versus transcellular intestinal permeability to gliadin peptides in active celiac disease. Am J Pathol 2012;180: 608-15
27. Paterson BM, Lammers KM, Arrieta MC, et al. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects: A proof of concept study. Aliment Pharmacol Ther 2007;26:757-66
28. Hausch F, Shan L, Santiago NA, et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Physiol 2002;283: G996-G1003
29. Gass J, Bethune MT, Siegel M, et al. Combination enzyme therapy for gastric digestion of dietary gluten in patients with celiac sprue. Gastroenterology 2007;133: 472-80
30. Bethune MT, Strop P, Tang Y, et al. Heterologous expression, purification, refolding, and structural-functional characterization of EP-B2, a self-activating barley cysteine endoprotease. Chem Biol 2006;13:637-47
31. Shan L, Marti T, Sollid LM, et al. Comparative biochemical analysis of three bacterial prolyl endopeptidases: implications for coeliac sprue. Biochem J 2004;383: 311-18
32. Siegel M, Garber ME, Spencer AG, et al. Safety, tolerability, and activity of ALV003: results from two phase 1 single, escalating-dose clinical trials. Dig Dis Sci 2012;57:440-50
33. Lähdeaho M-L, Kaukinen K, Laurila K, et al. Glutenase ALV003 attenuates gluten-induced mucosal injury in patients with celiac disease. Gastroenterology 2014;146:1649-58
34. Evaluation of the efficacy and safety of ALV003 in symptomatic in celiac disease patients. Available from https://clinicaltrials. gov/ct2/show/NCT01917630
35. Tack GJ, Van De Water JMW, Bruins MJ, et al. Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study. World J Gastroenterol 2013;19:5837-47
36. Effect of AN-PEP enzyme on gluten digestion. Available from https:// clinicaltrials.gov/ct2/show/NCT01335503
37. Effect of AN-PEP enzyme on gluten digestion in gluten sensitive individuals (AN-PEP-03). Available from https:// clinicaltrials.gov/ct2/show/NCT02060864
38. Korponay-Szabo I, Tumpek J, Gyimesi J, et al. Food-grade degrading enzymes to treat dietary transgressions in coeliac adolescents. J Pediatric Gastroenterology Nutrition Hepatology and Nutrition Annual Meeting; Istambul, Turkey; 2010. E68
39. Collado MC, Donat E, Ribes-Koninckx C, et al. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol 2008;8:232
40. Di Cagno R, De Angelis M, De Pasquale I, et al. Duodenal and faecal microbiota of celiac children: molecular, phenotype and metabolome characterization. BMC Microbiol 2011;11:219
41. Lindfors K, Blomqvist T, Juuti-Uusitalo K, et al. Live probiotic Bifidobacterium lactis bacteria inhibit the toxic effects induced by wheat gliadin in epithelial cell culture. Clin Exp Immunol 2008;152:552-8
42. Medina M, De Palma G, Ribes-Koninckx C, et al. Bifidobacterium strains suppress in vitro the pro-inflammatory milieu triggered by the large intestinal microbiota of coeliac patients. J Inflamm (Lond) 2008;5:19
43. De Palma G, Cinova J, Stepankova R, et al. Pivotal Advance: bifidobacteria and Gram-negative bacteria differentially influence immune responses in the proinflammatory milieu of celiac disease. J Leukoc Biol 2010;87:765-78
44. Smecuol E, Hwang HJ, Sugai E, et al. Exploratory, randomized, double-blind, placebo-controlled study on the effects of Bifidobacterium infantis natren life start strain super strain in active celiac disease. J Clin Gastroenterol 2013;47:139-47
45. Liang L, Pinier M, Leroux JC, et al. Interaction of alpha-gliadin with poly (HEMA-co-SS): structural characterization and biological implication. Biopolymers 2009;91:169-78
46. Liang L, Pinier M, Leroux JC, et al. Interaction of alpha-gliadin with polyanions: design considerations for sequestrants used in supportive treatment of celiac disease. Biopolymers 2010;93:418-28
47. Pinier M, Verdu EF, Nasser-Eddine M, et al. Polymeric binders suppress gliadin-induced toxicity in the intestinal epithelium. Gastroenterology 2009;136: 288-98
48. Mccarville JL, Nisemblat Y, Galipeau HJ, et al. BL-7010 demonstrates specific binding to gliadin and reduces gluten-associated pathology in a chronic mouse model of gliadin sensitivity. PLoS One 2014;9: e109972
49. Safety and systemic exposure study of BL-7010 in well-controlled celiac patients. Available from https://clinicaltrials.gov/ct2/ show/NCT01990885
50. Hmida NB, Ben Ahmed M, Moussa A, et al. Impaired control of effector T cells by regulatory T cells: A clue to loss of oral tolerance and autoimmunity in celiac disease? Am J Gastroenterol 2012;107: 604-11
51. Korneychuk N, Meresse B, Cerf-Bensussan N. Lessons from rodent models in celiac disease. Mucosal Immunol 2015;8:18-28
52. Marietta EV, David CS, Murray JA. Important lessons derived from animal models of celiac disease. Int Rev Immunol 2011;30:197-206
53. Schuppan D, Junker Y, Barisani D. Celiac disease: from pathogenesis to novel therapies. Gastroenterology 2009;137: 1912-33
54. Brown GJ, Daveson J, Marjason JK, et al. A Phase I Study to Determine Safety, Tolerability and Bioactivity of Nexvax2 in HLA DQ2+ Volunteers With Celiac Disease Following a Long-Term, Strict Gluten-Free Diet. Gastroenterology 2011;140:S-437-S-8
55. Strachan DP. Hay fever, hygiene, and household size. BMJ 1989;299:1259-60
56. Bach J-F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002;347:911-20
57. Fleming JO, Isaak A, Lee JE, et al. Probiotic helminth administration in relapsing-remitting multiple sclerosis: A phase 1 study. Mult Scler 2011;17:743-54
58. Summers RW, Elliott DE, Urban JF, et al. Trichuris suis therapy for active ulcerative colitis: A randomized controlled trial. Gastroenterology 2005;128:825-32
59. Bager P, Arnved J, Ronborg S, et al. Trichuris suis ova therapy for allergic rhinitis: A randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol 2010;125:123-30.e1-3
60. Feary JR, Venn AJ, Mortimer K, et al. Experimental hookworm infection: A randomized placebo-controlled trial in asthma. Clin Exp Allergy 2010;40:299-306
61. Daveson AJ, Jones DM, Gaze S, et al. Effect of hookworm infection on wheat challenge in celiac disease-A randomised double-blinded placebo controlled trial. PLoS One 2011;6:e17366
62. Croese J, Giacomin P, Navarro S, et al. Experimental hookworm infection and gluten microchallenge promote tolerance in celiac disease. J Allergy Clin Immunol 2014;135(2):508-16
63. Leffler D, Schuppan D, Pallav K, et al. Kinetics of the histological, serological and symptomatic responses to gluten challenge in adults with coeliac disease. Gut 2013;62: 996-1004
64. Keshav S, Vaňásek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS One 2013;8:e60094
65. A Phase II Study of CCX282-B in patients with celiac disease. Available from https:// clinicaltrials.gov/ct2/show/NCT00540657
66. Molberg O, Mcadam SN, Sollid LM. Role of tissue transglutaminase in celiac disease. J Pediatr Gastroenterol Nutr 2000;30: 232-40
67. Xia J, Siegel M, Bergseng E, et al. Inhibition of HLA-DQ2-mediated antigen presentation by analogues of a high affinity 33-residue peptide from alpha2-gliadin. J Am Chem Soc 2006;128:1859-67
68. Molberg O, Mcadam S, Lundin KEA, et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317-23
69. Choi K, Siegel M, Piper JL, et al. Chemistry and biology of dihydroisoxazole derivatives: selective inhibitors of human transglutaminase 2. Chem Biol 2005;12: 469-75
70. Rauhavirta T, Oittinen M, Kivistö R, et al. Are transglutaminase 2 inhibitors able to reduce gliadin-induced toxicity related to celiac disease? A proof-of-concept study. J Clin Immunol 2013;33:134-42
71. Lebreton C, Menard S, Abed J, et al. Interactions among secretory immunoglobulin A, CD71, and transglutaminase-2 affect permeability of intestinal epithelial cells to gliadin peptides. Gastroenterology 2012;143:698-707.e1-4
72. Elli L, Bergamini CM, Bardella MT, et al. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver. Dig Liver Dis 2009;41:541-50
73. Xia J, Bergseng E, Fleckenstein B, et al. Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in. 2008;15:6565-73
74. Kim C-Y, Quarsten H, Bergseng E, et al. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Natl Acad Sci USA 2004;101: 4175-9
75. Kapoerchan VV, Wiesner M, Overhand M, et al. Design of azidoproline containing gluten peptides to suppress CD4+ T-cell responses associated with celiac disease. Bioorg Med Chem 2008;16:2053-62
76. Kapoerchan VV, Wiesner M, Hillaert U, et al. Design, synthesis and evaluation of high-affinity binders for the celiac disease associated HLA-DQ2 molecule. Mol Immunol 2010;47:1091-7
77. Jüse U, Van De Wal Y, Koning F, et al. Design of new high-affinity peptide ligands for human leukocyte antigen-DQ2 using a positional scanning peptide library. Hum Immunol 2010;71:475-81
78. Siegel M, Bethune MT, Gass J, et al. Rational design of combination enzyme therapy for celiac sprue. Chem Biol 2006;13:649-58
79. Siegel M, Xia J, Khosla C. Structure-based design of alpha-amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorg Med Chem 2007;15:6253-61
80. Yokoyama S, Perera P-Y, Waldmann TA, et al. Tofacitinib, a janus kinase inhibitor demonstrates efficacy in an IL-15 transgenic mouse model that recapitulates pathologic manifestations of celiac disease. J Clin Immunol 2013;33:586-94
81. Lebrec H, Horner MJ, Gorski KS, et al. Homeostasis of human NK cells is not IL-15 dependent. J Immunol 2013;191: 5551-8
82. Antibody treatment for advanced celiac disease. Available from https://clinicaltrials. gov/ct2/show/NCT01893775
83. Mulder CJ, Wahab PJ, Meijer JW, et al. A pilot study of recombinant human interleukin-10 in adults with refractory coeliac disease. Eur J Gastroenterol Hepatol 2001;13:1183-8
84. Costantino G, Della Torre A, Lo Presti MA, et al. Treatment of life-threatening type I refractory coeliac disease with long-term infliximab. Dig Liver Dis 2008;40:74-7
85. Gillett HR, Arnott ID, Mcintyre M, et al. Successful infliximab treatment for steroid-refractory celiac disease: A case report. Gastroenterology 2002;122:800-5
86. Seven G, Assaad A, Biehl T, et al. Use of anti tumor necrosis factor-alpha monoclonal antibody for ulcerative jejunoileitis. World J Gastroenterol 2012;18:5135-7
87. Abraham M, Karni A, Dembinsky A, et al. In vitro induction of regulatory T cells by anti-CD3 antibody in humans. J Autoimmun 2008;30:21-8
88. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
89. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-88
90. Mei HE, Frölich D, Giesecke C, et al. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood 2010;116:5181-90
91. Safety Study of AT1001 to Treat Celiac Disease. Available from https://clinicaltrials. gov/ct2/show/NCT00386165
92. Safety of AT-1001 in healthy volunteers. Available from https://clinicaltrials.gov/ct2/ show/NCT00386490
93. Randomized, double-blind, placebo-controlled study of larazotide acetate (at-1001) in active celiac disease. Available from https://clinicaltrials.gov/ct2/ show/NCT00620451
94. Study of the efficacy of AT1001 (larazotide acetate) to treat celiac disease. Available from https://clinicaltrials.gov/ct2/show/ NCT00889473
95. Evaluation of patient reported outcome instruments in celiac disease patients. Available from https://clinicaltrials.gov/ct2/ show/NCT01560169